Dysarthria and apraxia of speech associated with FK-506 (Tacrolimus)

Bradley F. Boeve, David W. Kimmel, Arnold E. Aronson, Piet C. De Groen

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The immunosuppressive agent FK-506 (tacrolimus) is one of the agents most commonly used to prevent rejection after liver transplantation. Neurologic toxicity related to FK-506 has been reported, including speech disorders; however, a detailed analysis of the speech disorder associated with use of FK-506 has not been presented. Herein we describe a patient who exhibited mutism, then severe apraxia of speech with a concomitant hypokinetic, spastic, and ataxic dysarthria after administration of FK-506. His re-sidual mixed dysarthria, without radiographie evidence of a structural lesion, suggests dysfunction of one or more neurochemical systems. The pathophysiologic mechanisms underlying this intriguing entity remain obscure.

Original languageEnglish (US)
Pages (from-to)969-972
Number of pages4
JournalMayo Clinic Proceedings
Issue number10
StatePublished - 1996


  • Ct = computed tomography
  • Eeg = electroencephalography
  • Mri = magnetic resonance imaging


Dive into the research topics of 'Dysarthria and apraxia of speech associated with FK-506 (Tacrolimus)'. Together they form a unique fingerprint.

Cite this